Navigation Links
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Date:5/15/2012

313.6 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -the UK 323.7 Neuroendocrine Carcinoma Therapeutics Market Size (2005-2010)- France 333.8 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - France 343.9 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Germany 353.10 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Germany 363.11 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Italy 373.12 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Italy 383.13 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Spain 393.14 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Spain 403.15 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – Japan 413.16 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Japan 423.17 Drivers and Barriers for Neuroendocrine Carcinoma Therapeutics Market 433.17.1 Drivers for the Neuroendocrine Carcinoma Therapeutics Market 433.17.2 Barriers for the Neuroendocrine Carcinoma Therapeutics Market 433.18 Key Events Impacting the Future Market 443.19 Opportunity and Unmet Need 443.19.1 Gastrointestinal carcinoid (NETs) 453.19.2 Pancreatic NETs 453.20 Key Takeaway 464 Neuroendocrine Carcinoma Therapeutics Market- Competitive Assessment 474.1 Overview 474.1.1 Strategic Competitor Assessment 474.2 Product Profiles for the Major Marketed Products in Neuroendocrine Carcinoma 494.2.1 Afinitor (everolimus, RAD001) 494.2.2 Sutent (sunitinib) 504.2.3 Sandostatin LAR (octreotide acetate) 514.3 Key Takeaway 515 Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment 525.1 Overview 525.2 Strategic Pipeline Assessment 525.3 Analysis by Phase of Development 535.3.1 Neuroendocrine Carcinoma Therapeutics - Phase III Pipeline 535.3.2 Neuroendocrine Carcinoma Therapeutics - Phase II Pipeline 545.3.3 Neuroendocrine Carcinoma Therapeutics- Phase I Pipeline 545.3.4 Neuroendocrine Carcinoma Therapeutics -
'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
2. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
3. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
4. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
5. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
6. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
7. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Nematicide ... kill nematodes. Nematodes are microscopic parasitic roundworms, found ... and inside other plants and animals. Nematicides have ... or other properties promoting migration through the soil. ... than 1,000 plant-parasitic nematodes. With more than 10,000 ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader in ... test built upon research from their published P.A.I.N. Study. ... physicians with an objective way to understand theirs patient’s ... individuals. With this new test, physicians will be able ... that will affect their pain tolerance. , The P.A.I.N. ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, ... announced that it has received a Canadian Patent ... Actin-Sequestering Peptides.  This patent includes claims using thymosin ... other actin-sequestering peptides for these purposes.  The patent ... RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... Fast, semi-automatic creation of ... documents ChemAxon , a leader ... for life science research, launches ChemCurator, an application ... from documents. Markush structures are essential ... and understanding Markush structures is a difficult and ...
Breaking Biology Technology:Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2
... Inc. (Nasdaq: MLNM ) today announced the ... Board of Directors. Dr. Leiden, a,Managing Director at ... a distinguished career of more than 20 years ... to joining Clarus, Dr. Leiden,served as President and ...
... in fourth quarter -, SEATTLE, Oct. 4 ... collaborator Merck Serono, it,has reached agreement with the U.S. ... (SPA) to conduct a pivotal clinical trial with,the investigational ... nephritis. This is one of two clinical studies intended ...
... Oct. 3 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc.,(TSX: DDD; ... in both,prices and sales volumes for its main ... been operating near its maximum capacity,to meet rising ... ended August 31, 2007, the Company has,achieved significant ...
Cached Biology Technology:Life Sciences Leader Joins Millennium Board of Directors 2Life Sciences Leader Joins Millennium Board of Directors 3ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis 2ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis 3Strong Demand Pushes up Both Prices and Sales Volumes for Dragon's Main Products 2Strong Demand Pushes up Both Prices and Sales Volumes for Dragon's Main Products 3
(Date:9/30/2014)... goes wrong with your muscles because of age, disease or ... is. That,s where a new research report published in the ... comes in. In the report, a team of scientists ... help scientists "see" which genes are active in an organ ... activity and that men have approximately 400 more active genes ...
(Date:9/30/2014)... (September 30, 2014) People who suffer from asthma ... to control their asthma besides properly taking medications and ... article in the Annals of Allergy, Asthma and ... of Allergy, Asthma and Immunology (ACAAI), asthma sufferers can ... lifestyle. The woman described in the Annals article improved ...
(Date:9/29/2014)... Between 1970 and 2010 populations of mammals, birds, ... 52 percent, says the 2014 Living Planet Report ... biodiversity loss occurs disproportionately in low-income countriesand correlates ... , In addition to the precipitous decline in ... warning signs about the overall health of the ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2Half of global wildlife lost, says new WWF report 2
... climate change-induced northern migration of invasive marine is one ... opening day presentations at the First World Conference on ... in Valencia. Investigators report that invasive species of ... distance far greater than that covered by invasive terrestrial ...
... - A Purdue University researcher has created a compound that ... lead to a treatment for the disease. "The outbreak ... thousands of illnesses, and there is currently no treatment," said ... team. "Although it is not currently a threat, there is ...
... love sending and receiving text messages through their cell phones ... But now a new study from the University of North ... to reduce children,s chances of becoming overweight or obese later ... behaviors now. Recent studies show that approximately 19 ...
Cached Biology News:Marine invasive species advance 50 km per decade, World Conference on Marine Biodiversity told 2Marine invasive species advance 50 km per decade, World Conference on Marine Biodiversity told 3Marine invasive species advance 50 km per decade, World Conference on Marine Biodiversity told 4Purdue researcher invents molecule that stops SARS 2Purdue researcher invents molecule that stops SARS 3UNC study: Text messaging may help children fight off obesity 2UNC study: Text messaging may help children fight off obesity 3
PKC Sampler Kit 10 mu g each...
... Solid phase reagent for ... Easy & unique water ... with detergents and chaotropes; ... recover non-envelop viruses while ...
Tumor Suppressor Sampler Kit 10 mu g each...
Monoclonal Antibody toSynapsin I a and I b Neurofilament associated protein from mouse brain extracts (4)....
Biology Products: